



Press Release

ZEISS Vision Care acquires IP portfolio for electronic eyewear from Mitsui Chemicals

Move reinforces the company's commitment to remain at the forefront of technological advancements in the eyeglass lens industry

Aalen, Germany – 2 February 2024 – ZEISS Vision Care announces the successful acquisition of a comprehensive intellectual property (IP) portfolio, including a suite of patents, from Mitsui Chemicals (MCI). This strategic move solidifies ZEISS' commitment to advancing technology in the eyeglass lens industry and further opens new opportunities for the development of electro-active lenses and spectacle frames.

Modern eyeglass lenses can do much more for the eye than just correct visual defects. They can protect the eyes from harmful UV radiation, reduce perceived glare when driving, or reduce digital eye strain when working with computer screens. An innovative area for eye care will be the combination of electrically controlled functions with lenses and spectacles.

The acquired IP portfolio acquired from MCI comprises a range of groundbreaking patents that encompass various electric functionalities tailored for eyeglass lenses and frame electronics. This strategic investment aligns seamlessly with ZEISS' mission to enhance user experience and push the boundaries of technological innovation within the eyewear sector.

ZEISS Vision Care has a long-standing reputation for its dedication to research and development, consistently delivering state-of-the-art products that seamlessly blend form and function. This acquisition marks a significant milestone in ZEISS' innovation strategy as it gains access to more intellectual assets that will empower the company to develop new products for global markets. The electro-active functions covered by the acquired patents open up new possibilities for enhancing the functionality of eyeglass lenses, catering to the evolving needs of consumers in an increasingly digital and connected world.

While specific financial details of the transaction remain undisclosed, ZEISS expresses the invaluable contributions these acquired patents will make to its ongoing research and development initiatives as well as to its licensing business. "We are pleased to announce the acquisition of this exceptional IP portfolio from Mitsui Chemicals. This strategic move reinforces our commitment to remain at the forefront of technological advancements in the eyeglass lens industry," said Dr. Michael Hentschel, Global Head of Technology and Innovation at ZEISS Vision Care. "The acquired patents complement our existing capabilities and will play a pivotal role in shaping the future of eyeglass lens solutions for consumers worldwide."

**Press contact**

ZEISS Vision Care

Joachim Kuss

Phone: +49 151 42112288

E-Mail: joachim.kuss@zeiss.com

www.zeiss.com/vision-news

About ZEISS

ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling 10.1 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (status: 30 September 2023).

With around 43,000 employees, ZEISS is active globally in almost 50 countries with around 30 production sites, 60 sales and service companies and 27 research and development facilities. Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.

Further information at www.zeiss.com

ZEISS Vision Care

ZEISS Vision Care is one of the world's leading manufacturers of eyeglass lenses and ophthalmic instruments. The unit is allocated to the Consumer Markets segment and develops and produces offerings for the entire eyeglass value chain that are distributed globally under the ZEISS brand.